Why did Marksans defer the ₹100 crore capex?

Management said it has sufficient spare capacity to meet its near-term plans, making the expansion unnecessary for now.

Is the ₹4,000 crore revenue target for FY28 still on?

Yes, management reconfirmed it. That target was initially set when the capex plan was still active.

What is the biggest risk to the FY28 target?

Raw material inflation running at 20-25% per management's own commentary. It will pressure costs and could slow order inflows if the company can't pass it on.

What did management say about M&A?

The summary mentions due diligence on potential targets but gives no detail on size, valuation, or timeline. It is not clear if any deal is close.

Concalls · Pharmaceuticals · Mid cap

Marksans shelves ₹100 cr plant, sticks to ₹4,000 cr target

Management says existing plants have room to grow. The ambitious revenue goal for FY28 is unchanged, but raw-material costs are rising fast.

— 4 earlier stories on Marksans Pharma Ltd. →

MARKSANS By Tipsheet Editorial 27 May 2026 · 5:41 PM IST Verify on BSE · NSE

Mkt cap₹10,983 cr

P/E26.28×

ROE15.43%

Debt / eq.0.01

Div yld0.37%

₹100 cr Capacity-expansion capex now deferred.

What's new

Marksans has deferred a ₹100 crore capacity expansion, citing sufficient spare capacity.
The ₹4,000 crore revenue target for FY28 remains unchanged.
Management flagged 20-25% raw material inflation as a key headwind.

Why this matters

Deferring capex while chasing a stretch revenue target is a clear signal that execution will lean on existing assets, not new builds. It also tightens the timeline on the ₹4,000 crore goal: if spare capacity is the real constraint, hitting that number hinges on loading up current plants faster.

What we're watching

How raw material inflation at 20-25% impacts margins in coming quarters.
Whether M&A conversations turn into a deal to add capacity another way.
Utilisation rates at existing plants to justify the capex deferral.

The full read

Marksans Pharma is pausing its ₹100 crore capacity expansion. Management now says existing plants have enough spare room to hit its targets without new builds. That is a shift from prior guidance, and it narrows the path to the ₹4,000 crore revenue goal for FY28. Management is banking on loading up existing plants while fending off 20-25% raw material inflation. The deferral makes sense if spare capacity is real. It also puts more weight on the company's ability to win business fast. The concall summary notes M&A due diligence is underway, but it doesn't say on what or how close. The open question is whether Marksans can hit ₹4,000 crore by FY28 without spending on new plants.

Questions answered

Why did Marksans defer the ₹100 crore capex?: Management said it has sufficient spare capacity to meet its near-term plans, making the expansion unnecessary for now.
Is the ₹4,000 crore revenue target for FY28 still on?: Yes, management reconfirmed it. That target was initially set when the capex plan was still active.
What is the biggest risk to the FY28 target?: Raw material inflation running at 20-25% per management's own commentary. It will pressure costs and could slow order inflows if the company can't pass it on.
What did management say about M&A?: The summary mentions due diligence on potential targets but gives no detail on size, valuation, or timeline. It is not clear if any deal is close.

Mentioned: Marksans Pharma · ₹100 cr capex · ₹4,000 cr revenue target

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on MARKSANS →

27 May 2026 · 5:41 PM IST Marksans shelves ₹100 cr plant, sticks to ₹4,000 cr target
today Marksans plans ₹4,000 cr revenue by FY28, but the call transcript adds nothing new
8d ago Marksans closes FY26 with record ₹3,033 cr revenue as Q4 UK sales hit all-time high
8d ago Marksans Pharma profit jumps 60% on standalone basis for FY26
8d ago Marksans Pharma profit climbs 60% on standalone basis for FY26